Clinical outcomes in kidney transplant recipients receiving long-term therapy with inhibitors of the mammalian target of rapamycin

American Journal of Transplantation

Volumn 12, Issue 2, 2012, Pages 379-387

  Cortazar, F ^a   Molnar, M Z ^b,c   Isakova, T ^a   Czira, M E ^b   Kovesdy, C P ^d,e   Roth, D ^a   Mucsi, I ^b,f   Wolf, M ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c UCLA MEDICAL CENTER   (United States)

^d VETERANS AFFAIRS MEDICAL CENTER   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

Allograft loss; kidney transplantation; mortality; mTOR inhibitors

Indexed keywords

CALCINEURIN INHIBITOR; EVEROLIMUS; RAPAMYCIN;

ACUTE GRAFT REJECTION; ADULT; ALLOGRAFT; ARTICLE; BORDERLINE STATE; CONTROLLED STUDY; FEMALE; FOLLOW UP; GRAFT FAILURE; GRAFT RECIPIENT; HAZARD RATIO; HUMAN; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OBSERVATIONAL STUDY; POPULATION; PRIORITY JOURNAL; PROPENSITY SCORE; PROSPECTIVE STUDY; TREATMENT OUTCOME;

FEMALE; FOLLOW-UP STUDIES; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; HUNGARY; IMMUNOSUPPRESSIVE AGENTS; INCIDENCE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; POSTOPERATIVE CARE; PROSPECTIVE STUDIES; RISK FACTORS; SIROLIMUS; SURVIVAL RATE; TIME FACTORS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HOMOLOGOUS; TREATMENT OUTCOME;

EID: 84856427202     PISSN: 16006135     EISSN: 16006143     Source Type: Journal    
DOI: 10.1111/j.1600-6143.2011.03826.x     Document Type: Article

References (37)

1. Meier-Kriesche HU, Schold JD, Kaplan B,. Long-term renal allograft survival: Have we made significant progress or is it time to rethink our analytic and therapeutic strategies? Am J Transplant 2004; 4: 1289-1295. (Pubitemid 39013575)
2. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Allen RD, Chapman JR,. The natural history of chronic allograft nephropathy. N Engl J Med 2003; 349: 2326-2333. (Pubitemid 37509740)
3. DiJoseph JF, Mihatsch MJ, Sehgal SN,. Renal effects of rapamycin in the spontaneously hypertensive rat. Transpl Int 1994; 7: 83-88. (Pubitemid 24052381)
4. Morales JM, Wramner L, Kreis H, et al,. Sirolimus does not exhibit nephrotoxicity compared to cyclosporine in renal transplant recipients. Am J Transplant 2002; 2: 436-442.
5. Schuler W, Sedrani R, Cottens S, et al,. SDZ RAD, a new rapamycin derivative: Pharmacological properties in vitro and in vivo. Transplantation 1997; 64: 36-42. (Pubitemid 27327197)
6. Sehgal SN,. Rapamune (RAPA, rapamycin, sirolimus): Mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression. Clin Biochem 1998; 31: 335-340. (Pubitemid 28385231)
7. Kauffman HM, Cherikh WS, Cheng Y, Hanto DW, Kahan BD,. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005; 80: 883-889. (Pubitemid 41552882)
8. Rostaing L, Kamar N,. mTOR inhibitor/proliferation signal inhibitors: Entering or leaving the field? J Nephrol 2010; 23: 133-142.
9. Dean PG, Lund WJ, Larson TS, et al,. Wound-healing complications after kidney transplantation: A prospective, randomized comparison of sirolimus and tacrolimus. Transplantation 2004; 77: 1555-1561. (Pubitemid 38703037)
10. Kasiske BL, de Mattos A, Flechner SM, et al,. Mammalian target of rapamycin inhibitor dyslipidemia in kidney transplant recipients. Am J Transplant 2008; 8: 1384-1392. (Pubitemid 351989497)
11. Letavernier E, Legendre C,. mToR inhibitors-induced proteinuria: Mechanisms, significance, and management. Transplant Rev (Orlando) 2008; 22: 125-130. (Pubitemid 351372914)
12. Letavernier E, Pe'raldi MN, Pariente A, Morelon E, Legendre C,. Proteinuria following a switch from calcineurin inhibitors to sirolimus. Transplantation 2005; 80: 1198-1203. (Pubitemid 41746797)
13. Webster AC, Lee VW, Chapman JR, Craig JC,. Target of rapamycin inhibitors (sirolimus and everolimus) for primary immunosuppression of kidney transplant recipients: A systematic review and meta-analysis of randomized trials. Transplantation 2006; 81: 1234-1248.
14. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562-2575. (Pubitemid 350294223)
15. Kovesdy CP, Czira ME, Rudas A, et al,. Body mass index, waist circumference and mortality in kidney transplant recipients. Am J Transplant 2010; 10: 2644-2651.
16. Kovesdy CP, Molnar MZ, Czira ME, et al,. Associations between serum leptin level and bone turnover in kidney transplant recipients. Clin J Am Soc Nephrol 2010; 5: 2297-2304.
17. Molnar MZ, Czira ME, Rudas A, et al,. Association between the malnutrition-inflammation score and post-transplant anaemia. Nephrol Dial Transplant 2011; 26: 2000-2006.
18. Molnar MZ, Czira ME, Rudas A, et al,. Association of the malnutrition-inflammation score with clinical outcomes in kidney transplant recipients. Am J Kidney Dis 2011; 58: 101-108.
19. Molnar MZ, Keszei A, Czira ME, et al,. Evaluation of the malnutrition-inflammation score in kidney transplant recipients. Am J Kidney Dis 2010; 56: 102-111.
20. Jassal SV, Schaubel DE, Fenton SS,. Baseline comorbidity in kidney transplant recipients: A comparison of comorbidity indices. Am J Kidney Dis 2005; 46: 136-142. (Pubitemid 40848442)
21. K/DOQI. Clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-S201.
22. Fine J, Gray R,. A proportional hazards model for the subdistribution of competing risk. J Am Stat Assoc 1999; 94: 496-509.
23. Rosenbaum P, Rubin D,. The central role of the propensity score in observational studies for causal effects. Biometrika 1983; 70: 41-55.
24. Information for Healthcare Professionals: Sirolimus (marketed as Rapamune): FDA ALERT [06/11/2009].; Accessed on July 10, 2011
25. Vignot S, Faivre S, Aguirre D, Raymond E,. mTOR-targeted therapy of cancer with rapamycin derivatives. Ann Oncol 2005; 16: 525-537. (Pubitemid 40613318)
26. Yao JC, Shah MH, Ito T, et al,. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med 2011; 364: 514-523.
27. Araki M, Flechner SM, Ismail HR, et al,. Posttransplant diabetes mellitus in kidney transplant recipients receiving calcineurin or mTOR inhibitor drugs. Transplantation 2006; 81: 335-341. (Pubitemid 43255716)
28. Halloran PF,. Immunosuppressive drugs for kidney transplantation. N Engl J Med 2004; 351: 2715-2729. (Pubitemid 39665325)
29. Rui L,. A link between protein translation and body weight. J Clin Invest 2007; 117: 310-313. (Pubitemid 46203959)
30. Locatelli F, Pozzoni P, Del Vecchio L,. Renal replacement therapy in patients with diabetes and end-stage renal disease. J Am Soc Nephrol 2004; 15 (Suppl 1): S25-S29. (Pubitemid 38018450)
31. Ojo AO, Hanson JA, Wolfe RA, Leichtman AB, Agodoa LY, Port FK,. Long-term survival in renal transplant recipients with graft function. Kidney Int 2000; 57: 307-313. (Pubitemid 30227779)
32. Morice MC, Serruys PW, Sousa JE, et al,. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002; 346: 1773-1780. (Pubitemid 34586912)
33. Grimm RH, Jr., Svendsen KH, Kasiske B, Keane WF, Wahi MM,. Proteinuria is a risk factor for mortality over 10 years of follow-up. MRFIT Research Group. Multiple Risk Factor Intervention Trial. Kidney Int Suppl 1997; 63: S10-S14. (Pubitemid 28020423)
34. Bergkvist L, Adami HO, Persson I, Hoover R, Schairer C,. The risk of breast cancer after estrogen and estrogen-progestin replacement. N Engl J Med 1989; 321: 293-297. (Pubitemid 19193804)
35. Friis-Moller N, Sabin CA, Weber R, et al,. Combination antiretroviral therapy and the risk of myocardial infarction. N Engl J Med 2003; 349: 1993-2003.
36. Benson K, Hartz AJ,. A comparison of observational studies and randomized, controlled trials. N Engl J Med 2000; 342: 1878-1886. (Pubitemid 30419053)
37. Concato J, Shah N, Horwitz RI,. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med 2000; 342: 1887-1892. (Pubitemid 30419054)